318 related articles for article (PubMed ID: 36197988)
21. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2.
Wang R; Zhang Q; Zhang R; Aw ZQ; Chen P; Wong YH; Hong J; Ju B; Shi X; Ding Q; Zhang Z; Chu JJH; Zhang L
Front Immunol; 2022; 13():854952. PubMed ID: 35784344
[TBL] [Abstract][Full Text] [Related]
23. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
24. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
25. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS
Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns.
Gruell H; Vanshylla K; Korenkov M; Tober-Lau P; Zehner M; Münn F; Janicki H; Augustin M; Schommers P; Sander LE; Kurth F; Kreer C; Klein F
Cell Host Microbe; 2022 Sep; 30(9):1231-1241.e6. PubMed ID: 35921836
[TBL] [Abstract][Full Text] [Related]
27. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.
Wang Q; Iketani S; Li Z; Guo Y; Yeh AY; Liu M; Yu J; Sheng Z; Huang Y; Liu L; Ho DD
Cell Host Microbe; 2022 Nov; 30(11):1512-1517.e4. PubMed ID: 36108630
[TBL] [Abstract][Full Text] [Related]
28. An antibody from single human V
Luo S; Zhang J; Kreutzberger AJB; Eaton A; Edwards RJ; Jing C; Dai HQ; Sempowski GD; Cronin K; Parks R; Ye AY; Mansouri K; Barr M; Pishesha N; Williams AC; Vieira Francisco L; Saminathan A; Peng H; Batra H; Bellusci L; Khurana S; Alam SM; Montefiori DC; Saunders KO; Tian M; Ploegh H; Kirchhausen T; Chen B; Haynes BF; Alt FW
Sci Immunol; 2022 Oct; 7(76):eadd5446. PubMed ID: 35951767
[TBL] [Abstract][Full Text] [Related]
29. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
Roe TL; Brady T; Schuko N; Nguyen A; Beloor J; Guest JD; Aksyuk AA; Tuffy KM; Zhang T; Streicher K; Kelly EJ; Kijak GH
Microbiol Spectr; 2023 Mar; 11(2):e0033323. PubMed ID: 36877050
[TBL] [Abstract][Full Text] [Related]
30. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection.
Guenthoer J; Lilly M; Starr TN; Dadonaite B; Lovendahl KN; Croft JT; Stoddard CI; Chohan V; Ding S; Ruiz F; Kopp MS; Finzi A; Bloom JD; Chu HY; Lee KK; Overbaugh J
Proc Natl Acad Sci U S A; 2023 Jun; 120(23):e2220948120. PubMed ID: 37253011
[TBL] [Abstract][Full Text] [Related]
31. Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys.
Fenwick C; Turelli P; Ni D; Perez L; Lau K; Herate C; Marlin R; Lana E; Pellaton C; Raclot C; Esteves-Leuenberger L; Campos J; Farina A; Fiscalini F; Dereuddre-Bosquet N; Relouzat F; Abdelnabi R; Foo CS; Neyts J; Leyssen P; Lévy Y; Pojer F; Stahlberg H; LeGrand R; Trono D; Pantaleo G
Nat Microbiol; 2022 Sep; 7(9):1376-1389. PubMed ID: 35879526
[TBL] [Abstract][Full Text] [Related]
32. Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models.
Han Q; Wang S; Wang Z; Zhang C; Wang X; Feng N; Wang T; Zhao Y; Chi H; Yan F; Xia X
Virol Sin; 2023 Oct; 38(5):787-800. PubMed ID: 37423308
[TBL] [Abstract][Full Text] [Related]
33. Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2.
Pastorio C; Zech F; Noettger S; Jung C; Jacob T; Sanderson T; Sparrer KMJ; Kirchhoff F
Cell Host Microbe; 2022 Sep; 30(9):1255-1268.e5. PubMed ID: 35931073
[TBL] [Abstract][Full Text] [Related]
34. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
35. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses.
Li M; Ren Y; Aw ZQ; Chen B; Yang Z; Lei Y; Cheng L; Liang Q; Hong J; Yang Y; Chen J; Wong YH; Wei J; Shan S; Zhang S; Ge J; Wang R; Dong JZ; Chen Y; Shi X; Zhang Q; Zhang Z; Chu JJH; Wang X; Zhang L
Nat Commun; 2022 Dec; 13(1):7957. PubMed ID: 36575191
[TBL] [Abstract][Full Text] [Related]
36. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3.
Huang M; Wu L; Zheng A; Xie Y; He Q; Rong X; Han P; Du P; Han P; Zhang Z; Zhao R; Jia Y; Li L; Bai B; Hu Z; Hu S; Niu S; Hu Y; Liu H; Liu B; Cui K; Li W; Zhao X; Liu K; Qi J; Wang Q; Gao GF
Immunity; 2022 Aug; 55(8):1501-1514.e3. PubMed ID: 35777362
[TBL] [Abstract][Full Text] [Related]
37. Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination.
Chi X; Guo Y; Zhang G; Sun H; Zhang J; Li M; Chen Z; Han J; Zhang Y; Zhang X; Fan P; Zhang Z; Wang B; Zai X; Han X; Hao M; Fang T; Xu J; Wu S; Chen Y; Fang Y; Dong Y; Sun B; Zhang J; Li J; Zhao G; Yu C; Zhou Q; Chen W
Signal Transduct Target Ther; 2022 Apr; 7(1):139. PubMed ID: 35478188
[TBL] [Abstract][Full Text] [Related]
38. Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies.
Sheward DJ; Pushparaj P; Das H; Greaney AJ; Kim C; Kim S; Hanke L; Hyllner E; Dyrdak R; Lee J; Dopico XC; Dosenovic P; Peacock TP; McInerney GM; Albert J; Corcoran M; Bloom JD; Murrell B; Karlsson Hedestam GB; Hällberg BM
Cell Rep Med; 2024 Jun; 5(6):101577. PubMed ID: 38761799
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
[TBL] [Abstract][Full Text] [Related]
40. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
